Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate

S. R. Marder, M. Aravagiri, W. C. Wirshing, D. A. Wirshing, M. Lebell, Jim Mintz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate. Method: Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1-0.3, 0.3-0.6, 0.6-1.0 ng/ml) plasma levels of fluphenazine. The dose of fluphenazine decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. Results: All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of fluphenazine and clinical outcomes or side effects. Conclusion: Our results do not provide support for the usefulness of monitoring fluphenazine plasma levels for patients receiving fluphenazine decanoate.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalSchizophrenia Research
Volume53
Issue number1-2
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Fluphenazine
Physiologic Monitoring
Random Allocation
Antipsychotic Agents
Schizophrenia
Psychopathology
fluphenazine depot
Therapeutics

Keywords

  • Antipsychotic
  • Fluphenazine
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. / Marder, S. R.; Aravagiri, M.; Wirshing, W. C.; Wirshing, D. A.; Lebell, M.; Mintz, Jim.

In: Schizophrenia Research, Vol. 53, No. 1-2, 01.01.2002, p. 25-30.

Research output: Contribution to journalArticle

Marder, S. R. ; Aravagiri, M. ; Wirshing, W. C. ; Wirshing, D. A. ; Lebell, M. ; Mintz, Jim. / Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. In: Schizophrenia Research. 2002 ; Vol. 53, No. 1-2. pp. 25-30.
@article{aba42a3be0b049aab9971a07defebd00,
title = "Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate",
abstract = "Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate. Method: Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1-0.3, 0.3-0.6, 0.6-1.0 ng/ml) plasma levels of fluphenazine. The dose of fluphenazine decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. Results: All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of fluphenazine and clinical outcomes or side effects. Conclusion: Our results do not provide support for the usefulness of monitoring fluphenazine plasma levels for patients receiving fluphenazine decanoate.",
keywords = "Antipsychotic, Fluphenazine, Schizophrenia",
author = "Marder, {S. R.} and M. Aravagiri and Wirshing, {W. C.} and Wirshing, {D. A.} and M. Lebell and Jim Mintz",
year = "2002",
month = "1",
day = "1",
doi = "10.1016/S0920-9964(00)00184-5",
language = "English (US)",
volume = "53",
pages = "25--30",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate

AU - Marder, S. R.

AU - Aravagiri, M.

AU - Wirshing, W. C.

AU - Wirshing, D. A.

AU - Lebell, M.

AU - Mintz, Jim

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate. Method: Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1-0.3, 0.3-0.6, 0.6-1.0 ng/ml) plasma levels of fluphenazine. The dose of fluphenazine decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. Results: All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of fluphenazine and clinical outcomes or side effects. Conclusion: Our results do not provide support for the usefulness of monitoring fluphenazine plasma levels for patients receiving fluphenazine decanoate.

AB - Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate. Method: Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1-0.3, 0.3-0.6, 0.6-1.0 ng/ml) plasma levels of fluphenazine. The dose of fluphenazine decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. Results: All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of fluphenazine and clinical outcomes or side effects. Conclusion: Our results do not provide support for the usefulness of monitoring fluphenazine plasma levels for patients receiving fluphenazine decanoate.

KW - Antipsychotic

KW - Fluphenazine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0036132925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036132925&partnerID=8YFLogxK

U2 - 10.1016/S0920-9964(00)00184-5

DO - 10.1016/S0920-9964(00)00184-5

M3 - Article

C2 - 11728835

AN - SCOPUS:0036132925

VL - 53

SP - 25

EP - 30

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-2

ER -